Guillaume Cartron, Florence Hourcade-Potelleret, Franck Morschhauser, Gilles Salles, Michael Wenger, Anna Truppel-Hartmann, David J. Carlile. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. haematol [Internet]. 2016Feb.1 [cited 2024Apr.28];101(2):226-34. Available from: https://haematologica.org/article/view/7629